Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
Phase 4: testing Stopping dupilumab for Severe Asthma
Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months.
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Stopping dupilumab. The registry lists allocation as randomized. Asthma management has been revolutionised by the development of biological therapies.
They plan to enroll about 205 people at 29 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
WIthdrawal of DUpilumab in Severe Asthma: a Randomized Non-inferiority-controlled Trial
Treated with dupilumab for at least 36 months for severe asthma
Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit
Who the registry excludes
Patients who refuse to discontinue dupilumab, for any reason
Patients with Forced expiratory volume in one second ≤ 30% of predicted values
Patients treated by an oral corticosteroid dose ≥ 10 mg/day (in prednisone equivalent)
Patients who have to discontinue dupilumab for a reason other than controlled asthma, such as an adverse drug reaction, a planned or current pregnancy, or a planned switch to another biologic indicated in severe asthma
Patients who have to continue dupilumab for the treatment of comorbidities apart from nasal polyposis
This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.
Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation.
Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06818019?
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06818019?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.